These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
18. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase. Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619 [TBL] [Abstract][Full Text] [Related]
19. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819 [TBL] [Abstract][Full Text] [Related]
20. Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors. Peifer C; Urich R; Schattel V; Abadleh M; Röttig M; Kohlbacher O; Laufer S Bioorg Med Chem Lett; 2008 Feb; 18(4):1431-5. PubMed ID: 18207396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]